Low dose capecitabine plus weekly paclitaxel in patients with metastatic breast cancer: A multicenter phase II study KBCSG-0609

Cancer Chemotherapy and Pharmacology

Volumn 71, Issue 3, 2013, Pages 741-747

  Taguchi, Tetsuya ^a   Yamamoto, Daigo ^b   Masuda, Norikazu ^c   Oba, Koji ^d   Nakayama, Takahiro ^e   Nagata, Takuya ^f   Nomura, Masaya ^g   Yoshidome, Katsuhide ^h   Yoshino, Hiroshi ⁱ   Matsunami, Nobuki ^j   Miyashita, Masaru ^k   Furuya, Yoshihiko ^l   Ishida, Takanori ^m   Wakita, Kazuyuki ⁿ   Sakamoto, Junichi ^o   Noguchi, Shinzaburo ^e  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b KANSAI MEDICAL UNIVERSITY HOSPITAL   (Japan)

^c OSAKA NATIONAL HOSPITAL   (Japan)

^d HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

^e OSAKA UNIVERSITY   (Japan)

^f UNIVERSITY OF TOYAMA   (Japan)

^g OSAKA GENERAL MEDICAL CENTER   (Japan)

^h OSAKA POLICE HOSPITAL   (Japan)

ⁱ ISHIKAWA PREFECTURAL CENTRAL HOSPITAL   (Japan)

^j OSAKA ROSAI HOSPITAL   (Japan)

^k Konan Hospital   (Japan)

^l SAISEIKAI NAKATSU HOSPITAL   (Japan)

^m TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

ⁿ Chayamachi Lady's Clinic   (Japan)

^o NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

Capecitabine; Metastatic breast cancer; Paclitaxel; Phase II

Indexed keywords

CAPECITABINE; HORMONE RECEPTOR; PACLITAXEL; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; DEOXYCYTIDINE; DRUG DERIVATIVE; FLUOROURACIL;

ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERBILIRUBINEMIA; LEUKOPENIA; LOW DRUG DOSE; MONOTHERAPY; MOTOR NEUROPATHY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SENSORY NEUROPATHY; SIDE EFFECT; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING; BIOASSAY; BREAST TUMOR; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; METASTASIS; MIDDLE AGED; PATHOLOGY; PHASE 1 CLINICAL TRIAL; SAMPLE SIZE; SURVIVAL;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; ENDPOINT DETERMINATION; FEMALE; FLUOROURACIL; HAND-FOOT SYNDROME; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM METASTASIS; PACLITAXEL; SAMPLE SIZE; SURVIVAL ANALYSIS;

MLCS; MLOWN;

EID: 84875832885     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-2068-7     Document Type: Article

References (23)

1. O'Shaughnessy J (2005) Extending survival with chemotherapy in metastatic breast cancer. Oncologist 10(Suppl 3):20-29 (Pubitemid 43152727)
2. Mosconi P, Colozza M, De Laurentiis M, De Placido S, Maltoni M (2001) Survival, quality of life and breast cancer. Ann Oncol 12(Suppl 3):15-19
3. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishitsuka H (1998) Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34:1274-1281 (Pubitemid 28342121)
4. Stockler MR, Harvey VJ, Francis PA, Byrne MJ, Ackland SP, Fitzharris B, Van Hazel G, Wilcken NR, Grimison PS, Nowak AK, Gainford MC, Fong A, Paksec L, Sourjina T, Zannino D, Gebski V, Simes RJ, Forbes JF, Coates AS (2011) Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer. J Clin Oncol 29:4498-4504
5. Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H (1998) Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 4:1013-1019 (Pubitemid 28183404)
6. Endo M, Shinbori N, Fukase Y, Sawada N, Ishikawa T, Ishitsuka H, Tanaka Y (1999) Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5′-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models. Int J Cancer 83:127-134 (Pubitemid 29409488)
7. O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, Fumoleau P, Jones S, Lui WY, Mauriac L, Twelves C, Van Hazel G, Verma S, Leonard R (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20:2812-2823 (Pubitemid 34651510)
8. Batista N, Perez-Manga G, Constenla M, Ruiz A, Carabantes F, Castellanos J, Gonzalez Barón M, Villman K, Söderberg M, Ahlgren J, Casinello J, Regueiro P, Murias A (2004) Phase II study of capecitabine in combination with paclitaxel in patients with anthracycline-pretreated advanced/metastatic breast cancer. Br J Cancer 90:1740-1746 (Pubitemid 38725644)
9. Gradishar WJ, Meza LA, Amin B, Samid D, Hill T, Chen YM, Lower EE, Marcom PK (2004) Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: a multicenter phase II study. J Clin Oncol 22:2321-2327 (Pubitemid 41115388)
10. Blum JL, Dees EC, Chacko A, Doane L, Ethirajan S, Hopkins J, McMahon R, Merten S, Negron A, Neubauer M, Ilegbodu D, Boehm KA, Asmar L, O'Shaughnessy JA (2006) Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 24:4384-4390 (Pubitemid 46630975)
11. Blum JL, Dees EC, Vukelja SJ, Amare M, Gill DP, McMahon RT, Ilegbodu D, Asmar L, O'Shaughnessy JA (2007) Phase II trial of capecitabine and weekly paclitaxel in patients with metastatic breast cancer previously treated with every-3-week taxane therapy. Clin Breast Cancer 7:465-470 (Pubitemid 46424283)
12. Taguchi T, Nakayama T, Masuda N, Yoshidome K, Akagi K, Nishida Y, Yoshikawa Y, Ogino N, Abe C, Sakamoto J, Noguchi S, Kinki Breast Cancer Study Group (2010) Study of low-dose capecitabine monotherapy for metastatic breast cancer. Chemotherapy 56:166-170
13. Kusama M, Nomizu T, Aogi K, Yoshimoto M, Horikoshi N, Tabei T, Noguchi S, Miura S, Yoshimura N, Kimura M, Toyama K, Shin E (2010) Phase II study of 4-weekly capecitabine monotherapy in advanced/metastatic breast cancer. Breast Cancer 17:233-240
14. Masuda N, Taguchi T, Nakayama T, Shiba E, Watatani M, Kurebayashi J, Takatsuka Y, Sakamoto J, Noguchi S, Kinki Breast Cancer Study Group (KBCSG) (2008) Capecitabine and paclitaxel combination chemotherapy for inoperable or recurrent breast cancer: a phase I dose-finding study by the Kinki Breast Cancer Study Group. Cancer Chemother Pharmacol 61:989-995 (Pubitemid 351423126)
15. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
16. Common Terminology Criteria for Adverse Events (CTCAE v3.0) (2004) 2003 (Japanese translation JCOG/JCSP version, 2004). Int J Clin Oncol 9(Suppl III):1-82 (in Japanese)
17. Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, Osterwalder B, Burger HU, Brown CS, Griffin T (1999) Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17:485-493 (Pubitemid 29075232)
18. Taguchi, T. Nakayama, N. Masuda N, Yoshidome K, Akagi K, Nishida Y, Yoshikawa Y, Ogino N, Abe C, Sakamoto J, Noguchi S, Kinki Breast Cancer Study Group (2008) Low-dose capecitabine (X) monotherapy as first-line chemotherapy (CT) for metastatic breast cancer (MBC): KBCSG 0408. ASCO Breast Cancer Symposium, Washington DC, abstract 193
19. Harris LN, Broadwater G, Lin NU, Miron A, Schnitt SJ, Cowan D, Lara J, Bleiweiss I, Berry D, Ellis M, Hayes DF, Winer EP, Dressler L (2006) Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. Breast Cancer Res 8:R66 (Pubitemid 350201714)
20. Sezgin C, Karabulut B, Uslu R, Sanli UA, Goksel G, Zekioglu O, Ozdemir N, Goker E (2005) Potential predictive factors for response to weekly paclitaxel treatment in patients with metastatic breast cancer. J Chemother 17:96-103 (Pubitemid 40463764)
21. Gianni L, Baselga J, Eiermann W, Guillem Porta V, Semiglazov V, Lluch A, Zambetti M, Sabadell D, Raab G, Llombart Cussac A, Bozhok A, Martinez-Agulló A, Greco M, Byakhov M, Lopez Lopez JJ, Mansutti M, Valagussa P, Bonadonna G, European Cooperative Trial in Operable Breast Cancer Study Group (2005) Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clin Cancer Res 11:8715-8721 (Pubitemid 43005921)
22. Tanaka M, Takamatsu Y, Anan K, Ohno S, Nishimura R, Yamamoto Y, Masuda N, Mitsuyama S, Tamura K, Kyushu Breast Cancer Study Group (2010) Oral combination chemotherapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: a phase II study. Anticancer Drugs 4:453-458
23. Muss HB, Berry DA, Cirrincione CT, Theodoulou M, Mauer AM, Kornblith AB, Partridge AH, Dressler LG, Cohen HJ, Becker HP, Kartcheske PA, Wheeler JD, Perez EA, Wolff AC, Gralow JR, Burstein HJ, Mahmood AA, Magrinat G, Parker BA, Hart RD, Grenier D, Norton L, Hudis CA, Winer EP, CALGB Investigators (2009) Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med 360:2055-2065